Health-Related Quality of Life and Survival Outcomes of Pediatric Patients With Nonmetastatic Osteosarcoma Treated in Countries With Different Resources

Michael W Bishop, Shailesh M Advani, Milena Villarroel, Catherine A Billups, Fariba Navid, Cecilia Rivera, Juan A Quintana, Jami S Gattuso, Pamela S Hinds, Najat C Daw, Michael W Bishop, Shailesh M Advani, Milena Villarroel, Catherine A Billups, Fariba Navid, Cecilia Rivera, Juan A Quintana, Jami S Gattuso, Pamela S Hinds, Najat C Daw

Abstract

Purpose: Health-related quality of life (HRQOL) improves throughout treatment of patients with nonmetastatic osteosarcoma. We compared HRQOL for patients in the United States and Chile treated on an international trial (OS99) with polychemotherapy and surgery, and we assessed the relationships among HRQOL measures, event-free survival (EFS), and overall survival (OS).

Materials and methods: Patients with newly diagnosed, localized osteosarcoma and their parents completed three HRQOL instruments (PedsQL v.4, PedsQL Cancer v.3, and Symptom Distress Scale [SDS]). Data were collected at four time points throughout therapy. Repeated measures models were used to investigate the effect of treatment site on instrument scores. The log-rank test examined the impact of treatment site on survival outcomes, and Cox proportional hazards regression models evaluated baseline HRQOL measures as predictors of EFS and OS.

Results: Of 71 eligible patients, 66 (93%) participated in the HRQOL studies in the United States (n = 44) and Chile (n = 22). The median age was 13.4 years (range, 5 to 23 years). Clinical characteristics were similar between treatment sites. US patients reported better scores for physical ( P = .030), emotional ( P = .027), and school functioning ( P < .001). Chilean patients reported poorer scores for worry ( P < .001) and nausea ( P = .007). Patient and parent nausea scores were similar between patients treated in the United States and Chile by the end of therapy. Differences in symptom distress were not observed between the countries. Neither HRQOL measures nor treatment site were associated with EFS or OS.

Conclusion: Although significant differences in HRQOL were observed between countries, outcomes were similar, and HRQOL measures were not associated with prognosis.

Figures

Fig 1
Fig 1
Event-free survival over time, demonstrated as a Kaplan-Meier curve for patients by country (United States v Chile).
Fig 2
Fig 2
Overall survival over time, demonstrated as a Kaplan-Meier curve for patients by country (United States v Chile).

References

    1. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results program. Cancer. 2009;115:1531–1543.
    1. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: The Memorial Sloan Kettering experience. J Clin Oncol. 1992;10:5–15.
    1. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004–2011.
    1. Daw NC, Neel MD, Rao BN, et al. Frontline treatment of localized osteosarcoma without methotrexate: Results of the St Jude Children’s Research Hospital OS99 trial. Cancer. 2011;117:2770–2778.
    1. Eiser C, Jenney M. Measuring quality of life. Arch Dis Child. 2007;92:348–350.
    1. Varni JW, Burwinkle TM, Lane MM. Health-related quality of life measurement in pediatric clinical practice: An appraisal and precept for future research and application. Health Qual Life Outcomes. 2005;3:34.
    1. Hinds PS, Billups CA, Cao X, et al. Health-related quality of life in adolescents at the time of diagnosis with osteosarcoma or acute myeloid leukemia. Eur J Oncol Nurs. 2009;13:156–163.
    1. Hinds PS, Gattuso JS, Billups CA, et al. Aggressive treatment of non-metastatic osteosarcoma improves health-related quality of life in children and adolescents. Eur J Cancer. 2009;45:2007–2014.
    1. Quinten C, Coens C, Mauer M, et al. Baseline quality of life as a prognostic indicator of survival: A meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol. 2009;10:865–871.
    1. Quinten C, Martinelli F, Coens C, et al. A global analysis of multi-trial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites. Cancer. 2014;120:302–311.
    1. Varni JW, Seid M, Rode CA. The PedsQL: Measurement model for the pediatric quality of life inventory. Med Care. 1999;37:126–139.
    1. Varni JW, Limbers CA, Burwinkle TM. How young can children reliably and validly self-report their health-related quality of life? An analysis of 8,591 children across age subgroups with the PedsQL 4.0 generic core scales. Health Qual Life Outcomes. 2007;5:1.
    1. Varni JW, Lane MM, Burwinkle TM, et al. Health-related quality of life in pediatric patients with irritable bowel syndrome: A comparative analysis. J Dev Behav Pediatr. 2006;27:451–458.
    1. Varni JW, Seid M, Knight TS, et al. The PedsQL 4.0 generic core scales: Sensitivity, responsiveness, and impact on clinical decision making. J Behav Med. 2002;25:175–193.
    1. Varni JW, Limbers CA, Burwinkle TM. Parent proxy-report of their children’s health-related quality of life: An analysis of 13,878 parents’ reliability and validity across age subgroups using the PedsQL 4.0 generic core scales. Health Qual Life Outcomes. 2007;5:2.
    1. Varni JW, Burwinkle TM, Katz ER, et al. The PedsQL in pediatric cancer: Reliability and validity of the pediatric quality of life inventory generic core scales, multidimensional fatigue scale, and cancer module. Cancer. 2002;94:2090–2106.
    1. Hinds PS, Quargnenti A, Bush AJ, et al. An evaluation of the impact of a self-care coping intervention on psychological and clinical outcomes in adolescents with newly diagnosed cancer. Eur J Oncol Nurs. 2000;4:6–17, discussion 18-19.
    1. Hinds PS, Schum L, Srivastava DK. Is clinical relevance sometimes lost in summative scores? West J Nurs Res. 2002;24:345–353.
    1. Marchese VG, Ogle S, Womer RB, et al. An examination of outcome measures to assess functional mobility in childhood survivors of osteosarcoma. Pediatr Blood Cancer. 2004;42:41–45.
    1. Robert RS, Ottaviani G, Huh WW, et al. Psychosocial and functional outcomes in long-term survivors of osteosarcoma: A comparison of limb-salvage surgery and amputation. Pediatr Blood Cancer. 2010;54:990–999.
    1. Nagarajan R, Clohisy DR, Neglia JP, et al. Function and quality-of-life of survivors of pelvic and lower extremity osteosarcoma and Ewing sarcoma: The Childhood Cancer Survivor Study. Br J Cancer. 2004;91:1858–1865.
    1. Nagarajan R, Neglia JP, Clohisy DR, et al. Education, employment, insurance, and marital status among 694 survivors of pediatric lower extremity bone tumors: A report from the childhood cancer survivor study. Cancer. 2003;97:2554–2564.
    1. Kuhlthau KA, Pulsifer MB, Yeap BY, et al. Prospective study of health-related quality of life for children with brain tumors treated with proton radiotherapy. J Clin Oncol. 2012;30:2079–2086.
    1. Mitchell HR, Lu X, Myers RM, et al. Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: Results of Children’s Oncology Group study AALL0331. Int J Cancer. 2016;138:332–339.
    1. Coens C, van der Graaf WT, Blay JY, et al. Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy—a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group global network study (EORTC 62072) Cancer. 2015;121:2933–2941.
    1. Osoba D. Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol. 1994;12:608–616.
    1. Coates AS, Hürny C, Peterson HF, et al. Quality-of-life scores predict outcome in metastatic but not early breast cancer. J Clin Oncol. 2000;18:3768–3774.
    1. Efficace F, Therasse P, Piccart MJ, et al. Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: An international multicenter study. J Clin Oncol. 2004;22:3381–3388.
    1. Rivera GK, Quintana J, Villarroel M, et al. Transfer of complex frontline anticancer therapy to a developing country: The St Jude osteosarcoma experience in Chile. Pediatr Blood Cancer. 2008;50:1143–1146.
    1. Efficace F, Bottomley A, Smit EF, et al. Is a patient’s self-reported health-related quality of life a prognostic factor for survival in non–small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol. 2006;17:1698–1704.
    1. Park SH, Cho MS, Kim YS, et al. Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy. Qual Life Res. 2008;17:207–214.
    1. Meeske K, Katz ER, Palmer SN, et al. Parent proxy-reported health-related quality of life and fatigue in pediatric patients diagnosed with brain tumors and acute lymphoblastic leukemia. Cancer. 2004;101:2116–2125.
    1. Vance YH, Morse RC, Jenney ME, et al. Issues in measuring quality of life in childhood cancer: Measures, proxies, and parental mental health. J Child Psychol Psychiatry. 2001;42:661–667.
    1. Eiser C, Morse R. Can parents rate their child’s health-related quality of life? Results of a systematic review. Qual Life Res. 2001;10:347–357.
    1. Thissen D, Liu Y, Magnus B, et al. Estimating minimally important difference (MID) in PROMIS pediatric measures using the scale-judgment method. Qual Life Res. 2016;25:13–23.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi